Targeting specific kinases to improve treatment for acute myeloid leukemia
Official title: Targeting FL3 and SRC kinases for AML therapy
Funded at Icahn School of Medicine at Mount Sinai · NIH-10804681 · Data updated 2026-11-12
This study is looking at new treatments for people with acute myeloid leukemia (AML) who have a specific gene mutation, aiming to see if certain targeted medicines can help them respond better to treatment and lower the chances of their cancer coming back.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $187,642 |
| NIH project number | 5R21CA252366-02 |
| Project ID | NIH-10804681 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have the FLT3-ITD mutation.
✕Less likely to help
Patients with AML who do not have the FLT3-ITD mutation may not benefit from this specific research.
What this research studies
This research focuses on improving therapies for patients with acute myeloid leukemia (AML), particularly those with a specific genetic mutation known as FLT3-ITD. The approach involves using targeted small molecules that inhibit FLT3 and SRC kinases, which are believed to contribute to the survival of AML cells. By investigating the effectiveness of these inhibitors, the research aims to enhance treatment responses and reduce relapse rates in patients. The study will utilize in vitro models and may involve animal testing to evaluate the potential benefits of these targeted therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with FLT3-ITD positive AML, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in targeting FLT3 and SRC kinases, indicating that this approach could lead to significant advancements in AML treatment.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Reddy, E Premkumar — Icahn School of Medicine at Mount Sinai
- Study coordinator: Reddy, E Premkumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.